Outlook Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
187.1M
on 2026-06-30, from 22.0M on 2024-03-31 10-Q ↗
a raise that quarter, at its price
Newest
S-3 of 2024-04-26. Not read yet. S-3 ↗
$100.0M
H.C. Wainwright, agreement of 2026-05-13. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Warrants
The 10-Q filed 2026-08-18 is not read yet.
Cash
0.8 quarters
$11.2M on 2026-06-30 ÷ $14.0M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-08-12 | Public offering with warrants at $1.10 | 55,555,556 | $0.99 | $55.0M | 424B5 ↗ |
| 2026-05-28 | Public offering | 8,539,709 | not read | not read | 424B5 ↗ |
| 2026-04-22 | Public offering with warrants at $0.31 | 16,129,033 | $0.31 | $5.0M | 424B5 ↗ |
| 2026-04-22 | Registered direct offering | 16,129,033 | not read | not read | 8-K ↗ |
| 2026-03-23 | Public offering with warrants at $0.25 | 20,000,000 | $0.25 | $5.0M | 424B5 ↗ |
| 2025-05-22 | Public offering with warrants at $1.40 | 9,285,714 | $1.40 | $13.0M | 424B5 ↗ |
Also on file: a 1-for-10 reverse split, 2026-07-16 8-K ↗